Trauma exposure rather than posttraumatic stress disorder is associated with reduced baseline plasma neuropeptide-Y levels

Biological Psychiatry

Volumn 54, Issue 10, 2003, Pages 1087-1091

  Morgan III, Charles A ^a,e   Rasmusson, Ann M ^a   Winters, Brendon ^a   Hauger, Richard L ^b   Morgan, Jeffrey ^c   Hazlett, Gary ^d   Southwick, Steven ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Spec Forces Underwater Warfare O   (United States)

^d JFK Special Warfare Training Center and School   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Military active duty; Military stress; Peptides; Resilience; Stress vulnerability; Veterans

Indexed keywords

NEUROPEPTIDE Y; YOHIMBINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MALE; NORMAL HUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOTRAUMA; SOLDIER; SYMPTOM;

EID: 0242391909     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(03)00433-5     Document Type: Article

References (25)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed: 1994;American Psychiatric Association, Washington, DC.
2. Bannon A.W., Seda J., Carmouche M., Francis J.M., Norman M.H., Karbon B., et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 868:2000;79-87.
3. Britton K.T., Akwa Y., Southerland S., Koob G.F. Neuropeptide Y blocks the "anxiogenic-like" behavioral action of corticotropin-releasing factor. Peptides. 21:2000;37-44.
4. Britton K.T., Southerland S., Van Uden E., Kirby D., Rivier J., Koob G. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology (Berl). 132:1997;6-13.
5. Corder R., Castagne V., Rivet J.-M., Mormede P., Gaillard R.C. Central and peripheral effects of repeated stress and high NaCl diet on neuropeptide Y. Physiol Behav. 52:1992;205-210.
6. Dotsch A.J., Englaro P., Dotsch A., Hanze J., Blum W.F., Kiess W., et al. Relation of leptin and neuropeptide-Y in human blood and cerebrospinal fluid. J Neurol Sci. 151:1997;185-188.
7. Ehlers C.L., Somes C., Seifritz E., Rivier J.E. CRF/NPY interactions A potential role in sleep dysregulation in depression and anxiety . Depress Anxiety. 6:1997;1-9.
8. Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept. 59:1995;201-205.
9. Heilig M., Koob G.F., Britton K.T. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides, in an operant conflict test. Regul Pept. 41:1992;65-69.
10. Heilig M., McLeod S., Brot M., Heinrichs S., Menzaghi F., Koob G., et al. Anxiolytic-like action of neuropeptide Y Mediation by Y1 receptors in amygdala, and dissociation from food intake effects . Neuropsychomarmacology. 8:1993;357-363.
11. Heilig M., Soderpalm B., Engel J., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl). 98:1989;524-529.
12. Heilig M., Widerlov E. Neuropeptide Y An overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses . Acta Psychiatr Scand. 82:1990;95-114.
13. Keane T.M., Fairbank J.A., Caddell J.M., Zimering R.T., Taylor K.L., Mora C.A. Clinical evaluation of a measure to assess combat exposure. Psychol Assess. 1:1989;53-55.
14. Morgan C.A. III, Rassmuson A., Wang S., Hoyt G., Hauger R., Hazlett G. NPY, cortisol and subjective distress in humans exposed to acute stress Replication and extension of previous report . Biol Psychiatry. 52:2002;136-142.
15. Morgan C.A. III, Wang S., Rassmuson A., Hazlett G., Anderson G., Charney D.S. Relationship among cortisol, catecholamines, neuropeptide-Y and human performance during exposure to uncontrollable stress. Psychosom Med. 63:2001;412-422.
16. Morgan C.A. III, Wang S., Southwick S.M., Rasmusson A., Hauger R., Charney D.S. Plasma neuropeptide-Y in humans exposed to acute uncontrollable stress. Biol Psychiatry. 47:2000;902-909.
17. Rasmusson A., Hauger R.L., Morgan C.A., Bremner J.D., Charney D.S., Southwick S.M. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-Related posttraumatic stress disorder. Biol Psychiatry. 47:2000;526-539.
18. Schnurr P.P., Vieilhauer M.J., Weathers F., Findler M. The Brief Trauma Questionnaire. 1999;National Center for PTSD, White River Junction, VT.
19. Southwick S.M., Bremner J.D., Rasmusson A., Morgan C.A. III, Arnsten A., Charney D.S. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry. 46:1999;1192-1204.
20. Southwick S.M., Krystal J.H., Bremner J.D., Morgan C.A. III, Nicolaou A.L., Nagy L.M., et al. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry. 54:1997;749-758.
21. Southwick S.M., Krystal J.H., Morgan C.A., Johnson D.R., Nagy L.M., Nicolaou A., et al. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry. 50:1993;266-274.
22. Wahlestedt C., Pich E.M., Koob G.F., Yee F., Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 259:1993;528-530.
23. Wahlestedt C., Reis D. Neuropeptide Y-related peptides and their receptors - are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol. 32:1993;309-352.
24. Weiss D., Marmar C. Wilson J., Keane T. The Impact of Event Scale-Revised Assessing Psychological Trauma and PTSD . 1997;399-411 Guilford, New York, NY.
25. Widerlov D., Lindstrom L.H., Wahlestedt C., Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal markers for major depression and schizophrenia, respectively. J Psychiatr Res. 22:1988;69-79.